TP53 and cancer: Especially in the case of “clearly” intermediate-risk population (greatly lowering the pre-test cancer probability in comparison with BRCA or TP53 mutation carriers) and in the absence of any correlate at reassessed MX and targeted US, we hypothesized that the residual cancer rate could be sufficiently low to postpone the MRI to the year after.